A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with REGN2810 or isatuximab alone in patients with advanced malignancies

Type of Cancer
Unknown

Sponsor
Sannofi Aventis

Protocol Number
ACT15319

To Learn More Call
(201)-510-0950